LIVIVO - Search results -

Search results

Result 1 - 10 of total 97

Search options

Article ; Online: Andexanet Alfa Neutralizes the Anticoagulant Effects of Unfractionated Heparin of Bovine, Ovine and Porcine Origin Almost as Protamine Sulfate.

Siddiqui, Fakiha / Hoppensteadt, Debra / Jeske, Walter / Ramacciotti, Eduardo / Tafur, Alfonso / Fareed, Jawed

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

2024 Volume 30, Page(s) 10760296241247558

Abstract: Introduction: Andexanet alfa (AA) - zhzo, recombinant coagulation factor Xa, is an approved antidote for oral Xa inhibitors (apixaban and rivaroxaban). Unfractionated heparin (UFH) is commonly used for therapeutic, interventional, and surgical ... ...

Abstract	Introduction: Andexanet alfa (AA) - zhzo, recombinant coagulation factor Xa, is an approved antidote for oral Xa inhibitors (apixaban and rivaroxaban). Unfractionated heparin (UFH) is commonly used for therapeutic, interventional, and surgical indications. Protamine sulfate (PrSO Materials and methods: The neutralization effect of PrSO Results: In the whole blood ACT studies, all three heparins produced strong anti-coagulant effects (400-450 seconds) compared to saline (130-150 seconds). Both AA and PrSO Conclusion: Andexanet alfa at 100 µg/ml effectively neutralizes the therapeutic and surgical/interventional concentrations of heparins in
MeSH term(s)	Animals ; Cattle ; Protamines/pharmacology ; Heparin/pharmacology ; Sheep ; Factor Xa/metabolism ; Recombinant Proteins/pharmacology ; Anticoagulants/pharmacology ; Swine ; Humans ; Blood Coagulation/drug effects ; Factor Xa Inhibitors/pharmacology
Chemical Substances	Protamines ; Heparin (9005-49-6) ; Factor Xa (EC 3.4.21.6) ; Recombinant Proteins ; Anticoagulants ; PRT064445 ; Factor Xa Inhibitors
Language	English
Publishing date	2024-04-24
Publishing country	United States
Document type	Journal Article
ZDB-ID	1237357-6
ISSN	1938-2723 ; 1076-0296
ISSN (online)	1938-2723
ISSN	1076-0296
DOI	10.1177/10760296241247558
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4370: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Is it time for a specific score for venous thromboembolism risk assessment for non-solid tumors?

Macedo, Ariane Vieira Scarlatelli / Ramacciotti, Eduardo

Chinese clinical oncology

2019 Volume 8, Issue S1, Page(s) S26

MeSH term(s)	Female ; Humans ; Male ; Neoplasms/complications ; Risk Assessment ; Venous Thromboembolism/etiology ; Venous Thromboembolism/pathology
Language	English
Publishing date	2019-11-04
Publishing country	China
Document type	Editorial
ZDB-ID	2828547-5
ISSN	2304-3873 ; 2304-3865
ISSN (online)	2304-3873
ISSN	2304-3865
DOI	10.21037/cco.2019.10.01
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Rivaroxaban plus aspirin for cardiovascular protection: Rationale for the vascular dose and dual pathway inhibition.

Ramacciotti, Eduardo / Weitz, Jeffrey I

Thrombosis research

2019 Volume 184, Page(s) 44–49

Abstract: This review provides the rationale for dual pathway inhibition with the combination of low-dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg once daily) to reduce platelet activation. Such therapy has been ... ...

Abstract	This review provides the rationale for dual pathway inhibition with the combination of low-dose rivaroxaban (2.5 mg twice daily) to attenuate thrombin generation and aspirin (100 mg once daily) to reduce platelet activation. Such therapy has been licensed for secondary prevention in patients with coronary or peripheral artery disease.
MeSH term(s)	Female ; Humans ; Male ; Aspirin/pharmacology ; Aspirin/therapeutic use ; Cardiovascular Diseases/drug therapy ; Factor Xa Inhibitors/pharmacology ; Factor Xa Inhibitors/therapeutic use ; Platelet Activation ; Platelet Aggregation Inhibitors/pharmacology ; Platelet Aggregation Inhibitors/therapeutic use ; Prospective Studies ; Rivaroxaban/pharmacology ; Rivaroxaban/therapeutic use
Chemical Substances	Aspirin (R16CO5Y76E) ; Factor Xa Inhibitors ; Platelet Aggregation Inhibitors ; Rivaroxaban (9NDF7JZ4M3)
Language	English
Publishing date	2019-10-23
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	121852-9
ISSN	1879-2472 ; 0049-3848
ISSN (online)	1879-2472
ISSN	0049-3848
DOI	10.1016/j.thromres.2019.09.033
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 863: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Rivaroxaban for post-discharge thromboprophylaxis: the MARINER trial.

Ramacciotti, Eduardo / Fareed, Jawed

International angiology : a journal of the International Union of Angiology

2018 Volume 37, Issue 6, Page(s) 427–430

MeSH term(s)	Drug Administration Schedule ; Factor Xa Inhibitors/administration & dosage ; Factor Xa Inhibitors/adverse effects ; Hemorrhage/etiology ; Humans ; Patient Discharge ; Randomized Controlled Trials as Topic ; Rivaroxaban/administration & dosage ; Rivaroxaban/adverse effects ; Venous Thromboembolism/prevention & control
Chemical Substances	Factor Xa Inhibitors ; Rivaroxaban (9NDF7JZ4M3)
Language	English
Publishing date	2018-12-17
Publishing country	Italy
Document type	Editorial
ZDB-ID	604910-2
ISSN	1827-1839 ; 0392-9590
ISSN (online)	1827-1839
ISSN	0392-9590
DOI	10.23736/S0392-9590.18.04069-5
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1833: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Tratamiento de hipoparatiroidismo con parathormona recombinante humana [rhPTH(1-84)].

Ramacciotti, Constanza F / Pereyra, M Celina / Cohen, Eduardo N

Medicina

2020 Volume 80, Issue 3, Page(s) 289–291

Abstract: Hypoparathyroidism (HypoPT) is a rare disease characterized by low calcium and inappropriately low circulating parathormone levels. We present the case of a 25-year-old high-performance athlete male, with history of HypoPT after total thyroidectomy for ... ...

Title translation	Hypoparathyroidism treated with recombinant human parathyroid hormone [rhPTH(1-84)].
Abstract	Hypoparathyroidism (HypoPT) is a rare disease characterized by low calcium and inappropriately low circulating parathormone levels. We present the case of a 25-year-old high-performance athlete male, with history of HypoPT after total thyroidectomy for papillary thyroid carcinoma (T3 N1b M0) two years before, who was referred to our clinic for symptomatic hypocalcemia. The patient reported serum calcium average levels of 7mg%, presented symptoms of hypocalcemia at rest and had multiple hospital admissions. First, standard treatment was optimized by calcium supplementation up to 12g/d and active vitamin D, not showing clinical or biochemical improvement. Malabsorption and complications of chronic HypoPT were ruled out. The 36-Item Short Form Health Survey (SF-36) demonstrated an impaired quality of life (QoL). Full-length recombinant human parathyroid hormone [rhPTH(1-84)] therapy was started with 50υg/d subcutaneous, and later adjusted to 75υg/d and the oral treatment gradually decreased. Currently, he is asymptomatic, with serum calcium levels above 9mg%, without receiving oral medication. He performs sports activity and shows marked improvement in quality of life according to SF-36 questionnaire.
MeSH term(s)	Adult ; Calcitriol/therapeutic use ; Calcium-Regulating Hormones and Agents/therapeutic use ; Hormone Replacement Therapy/methods ; Humans ; Hypoparathyroidism/drug therapy ; Hypoparathyroidism/etiology ; Male ; Parathyroid Hormone/therapeutic use ; Thyroid Cancer, Papillary/complications ; Thyroid Cancer, Papillary/surgery ; Thyroid Neoplasms/complications ; Thyroid Neoplasms/surgery ; Thyroidectomy/adverse effects ; Vitamin D/therapeutic use
Chemical Substances	Calcium-Regulating Hormones and Agents ; Parathyroid Hormone ; Vitamin D (1406-16-2) ; Calcitriol (FXC9231JVH)
Language	Spanish
Publishing date	2020-05-13
Publishing country	Argentina
Document type	Case Reports
ZDB-ID	411586-7
ISSN	1669-9106 ; 0025-7680 ; 0325-951X
ISSN (online)	1669-9106
ISSN	0025-7680 ; 0325-951X
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 163: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: A novel therapeutic vaccine targeting the soluble TNFα receptor II to limit the progression of cardiovascular disease: AtheroVax™.

Iversen, Patrick L / Kipshidze, Nicholas / Kipshidze, Nodar / Dangas, George / Ramacciotti, Eduardo / Kakabadze, Zurab / Fareed, Jawed

Frontiers in cardiovascular medicine

2023 Volume 10, Page(s) 1206541

Abstract: The burden of atherosclerotic cardiovascular disease contributes to a large proportion of morbidity and mortality, globally. Vaccination against atherosclerosis has been proposed for over 20 years targeting different mediators of atherothrombosis; ... ...

Abstract	The burden of atherosclerotic cardiovascular disease contributes to a large proportion of morbidity and mortality, globally. Vaccination against atherosclerosis has been proposed for over 20 years targeting different mediators of atherothrombosis; however, these have not been adequately evaluated in human clinical trials to assess safety and efficacy. Inflammation is a driver of atherosclerosis, but inflammatory mediators are essential components of the immune response. Only pathogenic forms of sTNFR2 are acted upon while preserving the membrane-bound (wild-type) TNFR2 contributions to a non-pathogenic immune response. We hypothesize that the inhibition of sTNRF2 will be more specific and offer long-term treatment options. Here we describe pre-clinical findings of an sTNFR2-targeting peptide vaccine (AtheroVax™) in a mouse model. The multiple pathways to synthesis of the soluble TNFRII receptor (sTNFRII) were identified as sTNFRII(PC), sTNFRII(Δ7), and sTNFRII(Δ7,9). The sTNFRII(Δ7) peptide, NH2-DFALPVEKPLCLQR-COOH is specific to sTNFR2 based on an mRNA splice-variant in which exon 6 is joined to exon 8. The role of sTNFRII(Δ7) as a mediator of prolonged TNFα activity by preventing degradation and clearance was investigated. Inflammation is a critical driver of onset, progression and expansion of atherosclerosis. The TNFα ligand represents a driver of inflammation that is mediated by a splice variant of TNFR2, referred to as sTNFRII(Δ7). The multiple forms of TNFRII, both membrane bound and soluble, are associated with distinctly different phenotypes. sTNFRII(PC) and sTNFRII(Δ7) are not equivalent to etanercept because they lack a clearance mechanism. The unique peptide associated with sTNFRII(Δ7) contains a linear B-cell epitope with amino acids from both exon 6 and exon 8 supporting the vaccine design. Animal studies to evaluate the vaccine are ongoing, and results will be forthcoming. We describe a peptide vaccine targeting sTNFR2 in limiting the progression of atherosclerosis. A therapeutic vaccine limiting the progression of atherosclerosis will greatly contribute to the reduction in morbidity and mortality from cardiovascular disease. It is likely the vaccine will be used in combination with the current standards of care and lifestyle modifications.
Language	English
Publishing date	2023-07-18
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2781496-8
ISSN	2297-055X
ISSN	2297-055X
DOI	10.3389/fcvm.2023.1206541
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Porcine Mucosal Heparin Shortage Crisis! What Are the Options?

Fareed, Jawed / Jeske, Water / Ramacciotti, Eduardo

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis

2019 Volume 25, Page(s) 1076029619878786

MeSH term(s)	African Swine Fever ; Animals ; Drug Substitution ; Heparin/supply & distribution ; Intestinal Mucosa/chemistry ; Swine
Chemical Substances	Heparin (9005-49-6)
Language	English
Publishing date	2019-09-26
Publishing country	United States
Document type	Journal Article
ZDB-ID	1237357-6
ISSN	1938-2723 ; 1076-0296
ISSN (online)	1938-2723
ISSN	1076-0296
DOI	10.1177/1076029619878786
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4370: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism.

Comerota, Anthony J / Ramacciotti, Eduardo

The American journal of the medical sciences

2016 Volume 352, Issue 1, Page(s) 92–106

Abstract: Venous thromboembolism (VTE) is a prevalent, potentially fatal health problem. Although standard anticoagulant therapy is effective when compared with the newer direct oral anticoagulants (DOACs), it has disadvantages. Heparin and its derivatives must be ...

Abstract	Venous thromboembolism (VTE) is a prevalent, potentially fatal health problem. Although standard anticoagulant therapy is effective when compared with the newer direct oral anticoagulants (DOACs), it has disadvantages. Heparin and its derivatives must be administered parenterally, whereas use of oral vitamin K antagonists is complicated by unpredictable pharmacokinetics and pharmacodynamics, drug-food and drug-drug interactions and the requirement for frequent laboratory monitoring. Randomized phase 3 trials have demonstrated that patients receive similarly effective anticoagulation with the DOACs dabigatran, edoxaban, rivaroxaban and apixaban when compared with warfarin, with similar or reduced risk of bleeding. Extended therapy trials have consistently demonstrated superior effectiveness for DOAC treatment when compared with placebo in preventing VTE recurrence. This article presents a comprehensive review of the pharmacokinetics, pharmacodynamics and accumulated clinical trial evidence for each DOAC for short-term, long-term and extended VTE therapy, and it considers the potential implications these agents have for the clinical management of VTE.
MeSH term(s)	Administration, Oral ; Anticoagulants/pharmacokinetics ; Anticoagulants/pharmacology ; Anticoagulants/therapeutic use ; Hemorrhage/drug therapy ; Humans ; Venous Thromboembolism/drug therapy
Chemical Substances	Anticoagulants
Language	English
Publishing date	2016-07
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	82078-7
ISSN	1538-2990 ; 0002-9629
ISSN (online)	1538-2990
ISSN	0002-9629
DOI	10.1016/j.amjms.2016.03.018
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ua VI Zs.2/10: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19.

Schulman, Sam / Arnold, Donald M / Bradbury, Charlotte A / Broxmeyer, Lisa / Connors, Jean Marie / Falanga, Anna / Iba, Toshiaki / Kaatz, Scott / Levy, Jerrold H / Middeldorp, Saskia / Minichiello, Tracy / Nazy, Ishac / Ramacciotti, Eduardo / Resnick, Helaine E / Samama, Charles Marc / Sholzberg, Michelle / Thachil, Jecko / Zarychanski, Ryan / Spyropoulos, Alex C

Journal of thrombosis and haemostasis : JTH

2024

Abstract: Based on emerging evidence from the COVID-19 pandemic, the International Society on Thrombosis and Haemostasis (ISTH) guidelines for antithrombotic treatment in COVID-19 were published in 2022. Since then, at least 16 new randomized controlled trials ... ...

Abstract	Based on emerging evidence from the COVID-19 pandemic, the International Society on Thrombosis and Haemostasis (ISTH) guidelines for antithrombotic treatment in COVID-19 were published in 2022. Since then, at least 16 new randomized controlled trials have contributed additional evidence, which necessitated a modification of most of the previous recommendations. We used again the American College of Cardiology Foundation/American Heart Association methodology for assessment of level of evidence (LOE) and class of recommendation (COR). Five recommendations had the LOE upgraded to A and 2 new recommendations on antithrombotic treatment for patients with COVID-19 were added. Furthermore, a section was added to answer questions about COVID-19 vaccination and vaccine-induced immune thrombotic thrombocytopenia (VITT), for which studies have provided some evidence. We only included recommendations with LOE A or B. Panelists agreed on 19 recommendations, 4 for nonhospitalized, 5 for noncritically ill hospitalized, 3 for critically ill hospitalized, and 2 for postdischarge patients, as well as 5 for vaccination and VITT. A strong recommendation (COR 1) was given for (a) use of prophylactic dose of low-molecular-weight heparin or unfractionated heparin in noncritically ill patients hospitalized for COVID-19, (b) for select patients in this group, use of therapeutic-dose low-molecular-weight heparin/unfractionated heparin in preference to prophylactic dose, and (c) for use of antiplatelet factor 4 enzyme immunoassays for diagnosing VITT. A strong recommendation was given against (COR 3) the addition of an antiplatelet agent in hospitalized, noncritically ill patients. These international guidelines provide recommendations for countries with diverse healthcare resources and COVID-19 vaccine availability.
Language	English
Publishing date	2024-03-18
Publishing country	England
Document type	Practice Guideline
ZDB-ID	2112661-6
ISSN	1538-7836 ; 1538-7933
ISSN (online)	1538-7836
ISSN	1538-7933
DOI	10.1016/j.jtha.2024.02.011
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5805: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 295: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Medical management of stable peripheral artery disease: the COMPASS trial. Perspectives from a vascular standpoint.

Ramacciotti, Eduardo / Castelli, Valter / Walenga, Jeanine / Fareed, Jawed

International angiology : a journal of the International Union of Angiology

2018 Volume 37, Issue 4, Page(s) 255–260

Abstract: The late-breaking presentation of the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial at the European Society of Cardiology Congress in 2017 with a simultaneous publication in The New England Journal of Medicine ... ...

Abstract	The late-breaking presentation of the COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial at the European Society of Cardiology Congress in 2017 with a simultaneous publication in The New England Journal of Medicine described important information on the relative risk/benefit of combining anticoagulation with antiplatelet therapy in both coronary artery disease and/or peripheral artery disease (PAD) patients. In this special article, a review of the literature addressing the effects of antiplatelets and anticoagulants in symptomatic PAD patients focusing on the two most relevant clinical endpoints: major adverse cardiovascular events and major adverse limb events is addressed. In addition, a critical review of the COMPASS trial results, with emphasis on the PAD population is performed from a vascular surgery standpoint. It is concluded that this important study validated the combined anticoagulation/antiplatelet strategies in the management of vascular disorders including stable atherosclerotic patients. However, challenges in implementing this strategy in clinical practice are expected, with bleeding complications still remaining as major concern, particularly for vascular surgeons. Further studies with different combinations of different anticoagulants/antiplatelets, eventually on top of new strategies such as PCSK9 inhibition are warranted to address the significant unmet medical need in this population of symptomatic atherosclerotic patients.
MeSH term(s)	Anticoagulants/administration & dosage ; Anticoagulants/adverse effects ; Blood Coagulation ; Drug Therapy, Combination ; Humans ; Peripheral Arterial Disease/therapy ; Platelet Aggregation Inhibitors/administration & dosage ; Platelet Aggregation Inhibitors/adverse effects ; Randomized Controlled Trials as Topic ; Vascular Surgical Procedures
Chemical Substances	Anticoagulants ; Platelet Aggregation Inhibitors
Language	English
Publishing date	2018-05-09
Publishing country	Italy
Document type	Journal Article ; Review
ZDB-ID	604910-2
ISSN	1827-1839 ; 0392-9590
ISSN (online)	1827-1839
ISSN	0392-9590
DOI	10.23736/S0392-9590.18.03998-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1833: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito